Cambrex Bets $150M on Complex Drug Manufacturing Dominance

EAST RUTHERFORD, NJ – March 23, 2026 – Cambrex is launching a major $150 million, dual-continent investment to expand its manufacturing capabilities, signaling a significant move to dominate the high-stakes market for complex active pharmaceutical ingredients (APIs). The global contract development and manufacturing organization (CDMO) has finalized initial engineering studies for a new $120 million facility in Charles City, Iowa, and is advancing a concurrent $30 million expansion at its site in Milan, Italy.

These strategic initiatives are designed to meet the surging global demand for next-generation therapeutics, particularly highly potent APIs (HPAPIs), peptides, and controlled substances, positioning the company as a critical partner for pharmaceutical innovators.

The High-Stakes Race for Specialized API Production

Cambrex's substantial investments are a direct response to a seismic shift in the pharmaceutical landscape. The global CDMO market is experiencing explosive growth, projected to swell from $273.4 billion in 2026 to over $580 billion by 2034. This boom is driven by pharmaceutical companies increasingly outsourcing complex manufacturing to specialized partners capable of handling the intricate science behind modern medicines.

The most intense growth is concentrated in the specialized API segments Cambrex is targeting. The market for highly potent APIs, essential for targeted cancer therapies like antibody-drug conjugates (ADCs), is expanding at nearly 11% annually. These powerful compounds represented almost a quarter of all new drug filings in 2025, yet their production requires costly, high-containment facilities, leading more than 60% of drug developers to rely on CDMOs.

Simultaneously, the therapeutic peptide market—driven by blockbuster drugs for diabetes and obesity—is on a trajectory to become a nearly $300 billion industry by 2033. Manufacturing these complex molecules at commercial scale presents significant technical hurdles, from multi-step synthesis to intensive purification, creating a critical need for the specialized capacity Cambrex is building. By expanding its footprint, the company is positioning itself to compete directly with other industry heavyweights like Lonza, Bachem, and CordenPharma, all of whom are also racing to add capacity in this lucrative sector.

Bolstering the US Supply Chain from the Heartland

The centerpiece of the company's strategy is the $120 million expansion in Charles City, Iowa, a move that reinforces the site's status as one of the largest independent API facilities in the United States. Groundbreaking for the new plant is scheduled for late 2026.

The project will add a substantial 140,000 liters of new reactor capacity, boosting the site's large-scale manufacturing output by 20%. The facility will be equipped with state-of-the-art technology, including large and mid-scale reactors and advanced Hastelloy agitated filter dryers, specifically designed to handle complex chemical processes. This includes the production of controlled substances, a highly regulated field where Cambrex has deep expertise, as well as the commercial-scale manufacturing of peptides using advanced liquid-phase synthesis methods.

This investment is not just about adding volume; it's a strategic play that aligns with the growing national emphasis on reshoring pharmaceutical supply chains. By significantly enhancing domestic API production capabilities, Cambrex is helping to mitigate the risks associated with global supply disruptions and strengthen the security of the U.S. drug supply. The expansion is also expected to provide a significant economic boost to the region, building upon Cambrex’s existing role as a major employer and reinforcing Iowa’s position in the nation’s biomanufacturing ecosystem.

A Legacy of Innovation Continues in Milan

Complementing its American expansion, Cambrex is investing $30 million to enhance its European flagship site in Milan, Italy. The project, expected to be completed in the second half of 2027, focuses on adding new analytical development and process R&D capabilities while upgrading multiple production plants.

The Milan site, which is celebrating its 80th anniversary of operation this year, has a long history of supporting pharmaceutical innovation. The new investment aims to build on this legacy by equipping the facility to tackle the growing market demand for what the industry refers to as "tides"—peptides and oligonucleotides—as well as highly potent molecules and controlled substances.

"Our Milan, Italy site has a distinguished legacy of supporting pharmaceutical development and manufacturing, and this year marks its 80th anniversary of operation," commented Claudio Russolo, Chief Operating Officer at Cambrex. "We are committed to ongoing investments to meet the growing market demand for complex chemistries, including tides, highly potent molecules, and controlled substances."

The acquisition of additional land for future growth underscores a long-term commitment to the region. This dual-continent strategy provides pharmaceutical clients with geographically diversified and resilient supply chain options, a crucial advantage in an increasingly unpredictable global market.

The Science Behind the Strategy: Manufacturing Tomorrow's Cures

At its core, Cambrex’s $150 million bet is on the future of medicine. The specific capabilities being added in Iowa and Milan are essential for producing the next generation of life-changing therapies that target diseases at a molecular level.

Peptides and oligonucleotides ("tides") represent a paradigm shift from traditional small-molecule drugs. These therapies offer high specificity and improved safety profiles for treating complex conditions ranging from genetic disorders and cancer to metabolic diseases. However, their structural complexity makes large-scale manufacturing a formidable scientific and engineering challenge. The intricate, multi-step synthesis processes and the rigorous purification required to achieve therapeutic-grade purity demand the exact type of specialized expertise and advanced technology that Cambrex is installing.

The focus on HPAPIs addresses the continued dominance of oncology in drug development pipelines, where about 75% of new cancer drugs in development are high-potency. By expanding its capacity to handle these powerful compounds safely and efficiently, Cambrex is solidifying its role as a key enabler of cutting-edge cancer treatments. This strategic alignment of investment with the most advanced and challenging areas of pharmaceutical science ensures that the company is not just adding capacity, but building the critical infrastructure needed to bring tomorrow's most innovative medicines to patients worldwide.